VolitionRx Limited (VNRX) stock forecast & analysis
0.4465
NYSE American · USD
Down: -0.0545, -10.9%
1 analysis
- Open
- 0.4500
- Previous close
- 0.5010
- Day range
- 0.4333 – 0.4601
- 52-week range
- 0.3300 – 14.80
- Volume (shares)
- 11.80M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 14.42M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.14
- Market cap
- 6.44M
Market Scanner’s AI analysis of VolitionRx Limited (VNRX), updated August 2026: VolitionRx's Nu.Q® NETs biomarker validation and market expansion contrasted with revenue decline and bearish technicals.
Summary
VolitionRx's Nu.Q® NETs biomarker validation and market expansion contrasted with revenue decline and bearish technicals.
Recent analyses for VolitionRx (VNRX) covered advancements in diagnostic technology, including the validation of its Nu.Q® NETs biomarker in sepsis and expansion into new markets. These developments were discussed alongside a year-over-year quarterly revenue decline and a stock price trading significantly below its long-term moving averages, with bearish technical indicators.
VNRX news & sentiment
News reports highlighted significant progress in VolitionRx's diagnostic technology validation and market expansion, alongside strong commercial momentum. Social media discussions were not covered in the provided notes.
VNRX technical picture
The stock traded significantly below its 50-day and 200-day SMAs, showing strong downtrend over the medium to long term despite a recent 7-day increase. Momentum indicators like the RSI and MACD suggested bearish sentiment, while the MFI indicated strong selling pressure.
Fundamentals
VolitionRx Limited (VNRX) reported a year-over-year quarterly revenue decline. The company's latest reported quarter showed net and operating losses, with a negative TTM operating margin and a TTM profit margin of 0%.
Factors discussed — upside
- Landmark clinical validation of Nu.Q® NETs biomarker in sepsis.
- Expansion into new addressable markets through diagnostic validations.
- Strong commercial momentum across total addressable markets valued at over $27 billion.
- 7-day stock price change shows a +13.6% increase.
Factors discussed — risks
- Year-over-year quarterly revenue growth of -2.0%.
- Stock price significantly below 50-day and 200-day SMAs.
- Substantial 30-day change of -41.2% and 91-day change of -82.6%.
- RSI at 35.59, indicating room for further price decline.
- MACD below zero, indicating bearish momentum.
- Diagnostic technology validation
- Market expansion
- Revenue trends
- Technical price action
Summary updated .
VNRX technical indicators
Common technical indicators for VNRX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.94 | Price below |
| 10-day exponential moving average | 0.47 | Price below |
| Relative strength index (14-day) | 32.87 | Neutral |
| MACD line (12/26/9) | -0.1683 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.26 – 0.90 | Price inside the bands |
Analyses
Recent VNRX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for VolitionRx Limited?
- The bull case for VolitionRx is supported by the landmark clinical validation of its Nu.Q® NETs biomarker in sepsis and expansion into new addressable markets. Strong commercial momentum across significant total addressable markets and a recent 7-day stock price increase were also noted.
- What are the risks for VolitionRx Limited?
- Risks for VolitionRx include a year-over-year quarterly revenue decline and the stock price trading significantly below its 50-day and 200-day moving averages. The company has also experienced substantial price drops over the 30-day and 91-day periods, with a current RSI indicating room for further decline and bearish momentum shown by the MACD.
- Is VolitionRx Limited bullish or bearish?
- Recent AI analyses of VolitionRx Limited examined factors on both sides. Discussed upside: The bull case for VolitionRx is supported by the landmark clinical validation of its Nu.Q® NETs biomarker in sepsis and expansion into new addressable markets. Strong commercial momentum across significant total addressable markets and a recent 7-day stock price increase were also noted. Discussed risks: Risks for VolitionRx include a year-over-year quarterly revenue decline and the stock price trading significantly below its 50-day and 200-day moving averages. The company has also experienced substantial price drops over the 30-day and 91-day periods, with a current RSI indicating room for further decline and bearish momentum shown by the MACD. These are descriptive observations, not a recommendation.
- What is the latest sentiment on VolitionRx Limited?
- News reports highlighted significant progress in VolitionRx's diagnostic technology validation and market expansion, alongside strong commercial momentum. Social media discussions were not covered in the provided notes.
- Bundles used
- gemini-low-v2
Run a fresh VNRX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every VNRX.US report already in the library